Understanding Compounding Pharmacy Regulations for Peptides

Compounding pharmacy regulations determine which peptides a licensed pharmacy may legally prepare for an individual patient. Under federal law, a 503A pharmacy can generally compound only with ingredients that are part of an FDA-approved drug, have an official USP monograph, or appear on FDA's "503A bulks list." Many popular peptides fall into none of those categories, and their status has shifted repeatedly between 2023 and 2026 — so it is worth understanding what the rules are and where things stand as of this writing.

What Is Compounding?

Compounding is the preparation of a medication tailored to an individual patient — for example, a different strength, a dye-free version, or a drug not commercially available. Compounded drugs are not FDA-approved. FDA does not review them for safety or effectiveness before they are dispensed; instead, the system relies on rules about which ingredients pharmacies may use and how they prepare them.

There are two main types of compounding facilities:

• 503A pharmacies compound for individual patients based on a prescription. They are primarily overseen by state boards of pharmacy.
• 503B outsourcing facilities can produce larger batches, register with FDA, and follow federal manufacturing quality standards.

For a deeper comparison, see The FDA 503A vs 503B Pharmacy Distinction.

Compounding Pharmacy Regulations: Which Ingredients Are Allowed?

A 503A pharmacy may compound with a bulk drug substance only if it:

1. Is a component of an FDA-approved drug, or
2. Has an applicable United States Pharmacopeia (USP) or National Formulary monograph, or
3. Appears on FDA's list of bulk substances that may be used in compounding (the "503A bulks list").

Most research peptides are not in FDA-approved drugs and lack USP monographs, so their legal path depends on that third route. While FDA evaluates nominated substances, it sorts them into interim categories. Category 1 substances may be compounded during review. Category 2 substances raise significant safety concerns and should not be compounded.

Timeline: How Peptide Status Has Changed

• 2023: FDA placed many peptides in Category 2, including BPC-157, TB-500, KPV, Semax, LL-37, Dihexa, Melanotan II, MOTS-c, Epitalon, DSIP, PEG-MGF, injectable GHK-Cu, Kisspeptin-10, Ipamorelin, CJC-1295, AOD-9604, MK-677, Thymosin Alpha-1 and Selank.
• October and December 2024: FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against adding ipamorelin, MK-677, kisspeptin-10, CJC-1295 and AOD-9604 to the bulks list.
• April 15, 2026: FDA removed 12 peptides from Category 2 — BPC-157, LL-37, Dihexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax and TB-500 — so the advisory committee could review them. Removal is not permission to compound.
• July 2026: The PCAC recommended adding BPC-157, TB-500 and KPV (each 8–6), Semax (8–5), MOTS-c (7–5) and Epitalon (7–4) to the bulks list. It did not recommend DSIP (6–7). LL-37, Dihexa, Melanotan II and injectable GHK-Cu are scheduled for review before February 2027.

What About FDA-Approved Peptides?

Some peptides are FDA-approved drugs with established manufacturing and labeling: tesamorelin, bremelanotide (PT-141), semaglutide, tirzepatide and liraglutide among them. When an approved product exists, pharmacies generally may not compound "essentially copies" of it except in limited circumstances, such as a declared drug shortage. That is why compounding of semaglutide and tirzepatide expanded during the shortages and was sharply restricted after FDA declared those shortages resolved. You can read more in Are Peptides FDA-Approved? What Patients Need to Know.

What These Regulations Mean for Patients

"Research use only" is a red flag

Websites selling peptides "for research purposes only, not for human consumption" are operating outside the pharmacy system. These products are not made under pharmacy or pharmaceutical quality standards. Independent testing has found products with the wrong amount of peptide, the wrong peptide entirely, or bacterial contamination.

A legitimate pharmacy relationship looks different

When a compounded medication is appropriate and legal, it should involve:

• A prescription from a licensed clinician who has evaluated you
• A state-licensed pharmacy (or FDA-registered 503B facility)
• Clear labeling, lot numbers and storage instructions
• Willingness to share certificates of analysis and testing information

See Peptide Quality Control: What to Look For for a practical checklist.

What Comes Next

If FDA proceeds with rulemaking, it would typically propose adding specific peptides to the bulks list, take public comment, and then finalize a rule. Even then, those peptides would remain unapproved drugs — available through compounding with a valid prescription, but without the large clinical trials that support FDA-approved medicines. State laws on prescribing and administration would still apply. I follow this process closely; you can read my perspective in The Future of Peptide Regulation in the United States.

How Laeeq M.D. Handles Peptide Regulation

At Laeeq M.D., I only discuss therapies that can be obtained legally through appropriately licensed sources, and I explain the regulatory status of anything we consider. If a peptide is not currently available through a lawful pathway, I say so plainly — and we focus on the many evidence-based options that are.

Sources

• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, updated 2026
• FDA Advisory Committee Recommends Adding BPC-157 to Compounding List — American Med Spa Association, 2026

Book a Consultation

If you want clear, physician-led guidance on what is legal, safe and evidence-based for your goals, start with a full evaluation. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA. Book a consultation to review your options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.